PharmaShots | Incisive News in 3 Shots

Subscribe Now

Declines

The US FDA Declines to Approve Incyte's Retifanlimab to Treat Patients with Squamous Cell Carcinoma of the Anal Canal

The US FDA Declines to Approve Incyte's Retifanlimab to Treat Patients with Squamous Cell Carcinoma of the Anal Canal

July 26, 2021

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us